about
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of C...
Read More
4.65
0.28
(6.41%)
1.4M
XNAS Volume
XNAS 03 Sep, 2025 5:30 PM (EDT)
Board Meeting
The next board meeting for I-Mab - ADR is on 10 Sep 2025 for the purpose of H.C. Wainwright 27th Annual Global Investment Conference
See details
Not Eligible
Expensive Valuation
Technically Bullish
IMab ADR Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..